title: Vitamin D as an immune modulator in multiple sclerosis, a review.
abstract: The role of vitamin D in calcium homeostasis is well known. More recently vitamin D has become a topic of interest in immune regulation and multiple sclerosis. The main reason for this is the observed geographical distribution of multiple sclerosis. Areas with high sunlight exposure, the principal inducer of vitamin D synthesis, have a relatively low prevalence of multiple sclerosis and vice versa. Furthermore, low levels of the principal vitamin D metabolite (25-hydroxy vitamin D) in the circulation are associated with a high incidence of multiple sclerosis. Other epidemiological evidence also supports the view that vitamin D metabolites have an immune and disease modulating effect in multiple sclerosis. Experimental research in vitro and in animal models has further clarified the interaction of vitamin D metabolites with the immune system. The evidence obtained from these studies strongly supports a model in which vitamin D mediates a shift to a more anti-inflammatory immune response, and in particular to enhanced regulatory T cell functionality. In the current review we link the basic knowledge on vitamin D and immune regulation with the vitamin D related observations in multiple sclerosis. We conclude that there is a sound basis on which to initiate double-blind placebo-controlled trials that not only address the effect of vitamin D on the clinical outcome of multiple sclerosis, but also on the regulatory T cell compartment.
authors.affiliation: Department of Neurology, University Hospital Maastricht, Maastricht, The Netherlands. JSMOL@neurologie.azm.nl
authors.forename: Joost
authors.initials: J
authors.lastname: Smolders
authors.forename: Jan
authors.initials: J
authors.lastname: Damoiseaux
authors.forename: Paul
authors.initials: P
authors.lastname: Menheere
authors.forename: Raymond
authors.initials: R
authors.lastname: Hupperts
mesh_terms: D000818:Animals; D015519:Bone Density; D002112:Calcifediol / Q000097:blood; D002986:Clinical Trials as Topic; D004198:Disease Susceptibility; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy / Q000378:metabolism; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000502:physiology* / Q000627:therapeutic use; D015994:Incidence; D007249:Inflammation / Q000276:immunology / Q000378:metabolism; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000453:epidemiology / Q000276:immunology* / Q000378:metabolism; D011247:Pregnancy; D011248:Pregnancy Complications / Q000276:immunology; D018167:Receptors, Calcitriol / Q000235:genetics / Q000378:metabolism; D012621:Seasons; D013472:Sunlight; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D014807:Vitamin D / Q000502:physiology* / Q000627:therapeutic use; D014808:Vitamin D Deficiency / Q000453:epidemiology
chemical_list: D007155:Immunologic Factors; D018167:Receptors, Calcitriol; D014807:Vitamin D; D002112:Calcifediol